Some of the latest innovation trends are coming from the nation of Israel, as I’ve blogged about before. A new therapeutic vaccine was recently developed in that tiny nation, and it promises to keep up to 90 percent of cancers from coming back.
This kind of development is increasingly important as our population lives longer. Cancer is not easy to fight, though more medical breakthroughs are happening every day all around the world. But along with the breakthroughs, our bodies can learn how to outsmart some medical approaches that often kill normal cells while targeting malignant ones.
The Israeli company Vaxil BioTherapeutics has formulated a cancer vaccine that is currently in clinical trials at Hadassah University Medical Center in Jerusalem. Six years from now the vaccine could be available on a large scale if all goes well.
Right now the vaccine is being tested against a type of blood cancer called multiple myeloma. The medical community is hopeful that the vaccine could be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors.
Vaxil’s product called ImMucin, works by activating the immune system by training T-cells –– the immune cells that protect the body by searching out and destroying cells that have a specific molecule called MUC1. More than 90 percent of all cancers have MUC1 on their cells.
The company says that people who have cancers in an advanced stage will still need treatments like chemo or surgery to remove tumors, but just imagine if the cancer can be brought down to a manageable level for doctors to deal with.